Automated Reports and Custom Dashboards
Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production […]
Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production […]
This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported
In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear
244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable Read Post »
One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation.
Customer Success: DrugPatentWatch for Your Library Read Post »
Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey
DrugPatentWatch serves companies across the drug development-delivery sector. A common request among drug manufacturers, payers, and suppliers alike is anticipation
Customer Success: Will a generic version of a drug launch? And when? Read Post »
Changes in drug markets can create growth opportunities for API manufacturers and CDMOs alike. Whether change comes from generic entry,
Customer Success: API and CDMO Business Development Read Post »
DrugPatentWatch has deep resources to support patent prosecution and patent litigation, but it is also used by law firms for
Get fresh news and insights, drug patent expirations & more…